The Illumina TruSight Tumor-15 assay (TS15) uses next-generation sequencing (NGS) technology to detect clinically significant variants in targeted regions of 15 genes commonly associated with solid tumours.
Genetics - Molecular Oncology
1x EDTA (Lavender) dedicated to Genetics
Send to MONC
BRAF gene variant testing
EGFR gene variant testing
KIT gene variant testing
KRAS gene variant testing
NGS panel_Solid tumour
NRAS gene variant testing
Solid tumour NGS panel (TS15)
TS15 - Solid tumour NGS panel
TP53 gene variant testing
FFPET: 6x 5-micron unstained FFPET slides (non-adhesive/uncharged preferred) PLUS 1x H&E stained slide with the tumour area marked (minimum 30% tumour content is required).
Reported variants are clinically significant with respect to tumour type and therapeutic/diagnostic/prognostic interpretations (Tier 1 – PMID: 27993330) and have a frequency greater than 2.5%.
Clinical significance of variants is based on current medical and scientific knowledge and may change with future findings.
NOTE: This method does not distinguish between germline and somatic variants. If a germline variant is suspected, testing of the variant on a peripheral blood sample is recommended.
Genes/regions included in the Tumor-15 test
|Gene||Region covered||Cancers associated|
|AKT1||Exon 3 (partial)||Breast|
|BRAF||Exon 15 (partial)||Melanoma, colon, lung|
|EGFR||Focal amplification, exons 12 (partial), 18, 19, 20, 21 (partial)||Lung|
|ERBB2 (HER2)||Focal amplification, exons 14 (partial), 17, 18, 19, 20 (partial), 21 (partial), 24, 26||Breast, lung|
|FOXL2||Exon 1 (partial)||Ovary|
|GNA11||Exon 5 (partial)||Melanoma|
|GNAQ||Exon 5 (partial)||Melanoma|
|KIT||Exons 8, 9, 10, 11, 13, 14, 17, 18||Gastric, melanoma|
|KRAS||Exons 2 (partial), 3 (partial), 4||Colon, gastric, lung|
|MET||Focal amplification||Lung, colon, gastric|
|NRAS||Exons 2 (partial), 3 (partial), 4||Colon|
|PDGFRA||Exons 12, 14, 18||Gastric, melanoma|
|PIK3CA||Exons 10, 21||Lung, breast, prostate|
|TP53||All coding exons||Lung, melanoma, ovary, colon|
DNA extracted from FFPE tissue or blood/bone marrow is analysed using the Illumina TruSight Tumor-15 assay (TS15). This assay uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. This test can also be used for KIT gene variant detection in AML patients, BRAF gene variant detection in HCL patients and TP53 gene variant detection in CLL patients. Details of the genes and regions covered by the TS15 assay are shown above.
$605.61 (Exclusive of GST)